drugset / Trial / NCT00460317

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

NCT00460317

Phase 3 Terminated 1450 enrolled Amgen Takeda · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects with adenocarcinoma histology (adenocarcinoma subpopulation).

Timeline

Start
2007-07
Primary completion
2011-03
Completion
2013-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator motesanib Small molecule 125 mg Oral
Comparator Carboplatin Small molecule 600 mg/ml Intravenous
Comparator Paclitaxel Small molecule 200 mg/m2 Intravenous